专利快速检索-快速检索全球专利，免费商用专利数据库-IPRDB

1. 发明申请

WO2009039078A1 ASSESSING CONGESTIVE HEART RISK IN PATIENTS TREATED OR POTENTIALLY TO BE TREATED WITH A PEROXISOME-PROLIFERATOR-ACTIVATOR-RECEPTOR-GAMMA AGONIST OR A THIAZOLIDINEDIONE 审中-公开
标题翻译：评估治疗或潜在可能与过氧化物酶 - 促进剂 - 活化剂 - 受体 - 游离激素或噻唑烷二酮治疗的患者的心绞痛风险
公开(公告)号：WO2009039078A1
公开(公告)日：2009-03-26
申请号：PCT/US2008/076492
申请日：2008-09-16
申请人： BG MEDICINE, INC. , MCBURNEY, Robert, Nicholas , WANG, Shunguang , PLASTERER, Tom , MUNTENDAM, Pieter
发明人： MCBURNEY, Robert, Nicholas , WANG, Shunguang , PLASTERER, Tom , MUNTENDAM, Pieter
IPC分类号： G01N33/68
CPC分类号： G01N33/6893 , G01N2333/4724 , G01N2800/325
摘要： Methods are provided for assessing a patient being treated with a peroxisome - proliferator-activator-receptor-γ (PPAR-γ) agonist or a thiazolidinedione (TZD), or having a condition treatable with a peroxisome-proliferator-activator-receptor-γ agonist or a thiazolidinedione. Methods include measuring a galectin-3 concentration or a change in a galectin-3 concentration in a body fluid of a patient being treated with a peroxisome-proliferator-activator-receptor-γ agonist or a thiazolidinedione. A comparison to galectin-3 levels or changes in comparable patients provides information indicative of congestive heart risk.
摘要翻译：提供的方法用于评估用过氧化物酶体增殖物激活受体 - （PPAR-α）激动剂或噻唑烷二酮（TZD），或具有可用过氧化物酶体增殖物 - 激活因子 - 受体 - 激动剂或噻唑烷二酮。方法包括测量半抗原-3浓度或半抗原-3浓度在用过氧化物酶体增殖物激活因子受体 - α受体α治疗的患者的体液中的变化激动剂或噻唑烷二酮。与半乳凝素-3水平的比较或可比较患者的变化提供了表明充血性心脏病风险的信息。

2. 发明申请

WO2012106341A1 USE OF GALECTIN-3 FOR DETECTING AND PROGNOSING HEART FAILURE AFTER ACUTE CORONARY SYNDROME 审中-公开
标题翻译：使用GALECTIN-3用于检测和预防急性冠状动脉综合征后的心脏衰竭
公开(公告)号：WO2012106341A1
公开(公告)日：2012-08-09
申请号：PCT/US2012/023328
申请日：2012-01-31
申请人： BG MEDICINE, INC. , MUNTENDAM, Pieter
发明人： MUNTENDAM, Pieter
IPC分类号： G01N33/566 , G01N33/68
CPC分类号： G01N33/6887 , G01N2333/4724 , G01N2800/325 , G01N2800/50 , G01N2800/56
摘要： The present invention relates to the use of galectin-3 materials and methods for predicting the risk of heart failure in a subject with Acute Coronary Syndrome. The invention further relates to the use of galectin-3 in monitoring the efficacy of treatment for heart failure in a subject with Acute Coronary Syndrome.
摘要翻译：本发明涉及半乳凝素-3材料的应用和用于预测急性冠状动脉综合征患者心力衰竭风险的方法。本发明还涉及半乳凝素-3在急性冠状动脉综合征患者中用于监测治疗心力衰竭疗效的用途。

3. 发明申请

WO2012003475A1 STATIN THERAPY MONITORED BY GALECTIN- 3 MEASUREMENT 审中-公开
标题翻译：由GALECTIN-3测量监测的治疗
公开(公告)号：WO2012003475A1
公开(公告)日：2012-01-05
申请号：PCT/US2011/042846
申请日：2011-07-01
申请人： BG MEDICINE, INC. , MUNTENDAM, Pieter
发明人： MUNTENDAM, Pieter
IPC分类号： A61K31/505 , A61P9/00 , G01N33/50
CPC分类号： A61K31/505 , A61K31/40 , G01N33/6893 , G01N2333/4724 , G01N2800/324 , G01N2800/325 , G01N2800/52
摘要： Described herein are materials and methods for predicting and monitoring a heart failure patient's physiological response to treatment with a statin. More specifically, the present invention relates to the endogenous protein galectin-3 and its use as a predictor of response to treatment with 3-hydroxy-3-methylglutaryl coenzyme-A reductase inhibitors, or statins.
摘要翻译：本文描述了用于预测和监测心力衰竭患者对他汀类药物治疗的生理反应的材料和方法。更具体地，本发明涉及内源蛋白半乳凝素-3及其作为对用3-羟基-3-甲基戊二酰辅酶A还原酶抑制剂或他汀类药物治疗的反应的预测因子的用途。

4. 发明申请

WO2011116128A1 METHODS FOR PREDICTING CARDIOVASCULAR EVENTS AND MONITORING TREATMENT USING PCSK9 审中-公开
标题翻译：使用PCSK9预测心血管事件和监测治疗方法
公开(公告)号：WO2011116128A1
公开(公告)日：2011-09-22
申请号：PCT/US2011/028721
申请日：2011-03-16
申请人： BG MEDICINE, INC. , MUNTENDAM, Pieter
发明人： MUNTENDAM, Pieter
IPC分类号： G01N33/68
CPC分类号： G01N33/573 , A61K31/351 , C12Q1/37 , G01N2333/958 , G01N2333/96433 , G01N2500/00 , G01N2800/044 , G01N2800/32 , G01N2800/324 , G01N2800/50 , G01N2800/52 , G16H50/30
摘要： Methods are provided for diagnosing the risk of a cardiovascular event in a patient. In some embodiments, the method includes measuring the level of proprotein convertase subtilisin kexin type 9 (PCSK9) in a sample obtained from a patient and comparing the measured level of PCSK9 to a control. Also provided are methods of selecting a therapy for a patient prior to administration of the therapy. In some embodiments, the method includes measuring a PCSK9 blood concentration in a sample from a patient to determine the presence or absence of a PCSK9 blood concentration indicative of responsiveness to an inhibitor of 3-hydroxy-3- methylglutaryl-coenzyme A reductase. Further provided are methods for assessing the efficacy of a therapy being administered to a patient. In certain embodiments, the method includes detecting a change in a PCSK9 blood concentration in a sample from a patient, wherein a change in detected levels is indicative of whether the therapy is efficacious.
摘要翻译：提供了用于诊断患者心血管事件风险的方法。在一些实施方案中，该方法包括测量从患者获得的样品中的蛋白质转化酶枯草杆菌蛋白酶kexin 9型（PCSK9）的水平，并将PCSK9的测定水平与对照相比较。还提供了在施用治疗之前为患者选择治疗的方法。在一些实施方案中，该方法包括测量来自患者的样品中的PCSK9血液浓度，以确定是否存在指示对3-羟基-3-甲基戊二酰辅酶A还原酶的抑制剂的反应性的PCSK9血液浓度。还提供了评估给予患者的治疗效果的方法。在某些实施方案中，该方法包括检测来自患者的样品中PCSK9血液浓度的变化，其中所检测水平的变化指示治疗是否有效。

5. 发明申请

WO2011060361A1 RISK FACTORS AND PREDICTION OF MYOCARDIAL INFARCTION 审中-公开
标题翻译：风险因素和预测心肌梗塞
公开(公告)号：WO2011060361A1
公开(公告)日：2011-05-19
申请号：PCT/US2010/056711
申请日：2010-11-15
申请人： BG MEDICINE, INC. , ADOURIAN, Aram, S. , GUO, Yu , LI, Xiaohong , MUNTENDAM, Pieter
发明人： ADOURIAN, Aram, S. , GUO, Yu , LI, Xiaohong , MUNTENDAM, Pieter
IPC分类号： G01N33/50
CPC分类号： G01N33/6893 , G01N2800/324 , G01N2800/60
摘要： Biomarkers and methods are disclosed for diagnosing the risk of a myocardial infarction in an individual by measuring the levels of a set of biomarkers in a sample from an individual. A risk score is calculated for the individual by weighting the measured levels of the biomarkers. The risk score then is used to identify whether the individual is likely to experience a myocardial infarction. In addition, kits are disclosed that include a set of reagents for specifically measuring biomarker levels in a sample from an individual.
摘要翻译：公开了用于通过测量来自个体的样品中的一组生物标志物的水平来诊断个体心肌梗死的风险的生物标志物和方法。通过对生物标志物的测量水平加权来计算个体的风险评分。然后，风险分数用于确定个体是否可能经历心肌梗死。此外，公开了包括用于特异性测量来自个体的样品中的生物标志物水平的一组试剂的试剂盒。

6. 发明申请

WO2011031493A2 GALECTIN-3 AND CARDIAC RESYNCHRONIZATION THERAPY 审中-公开
标题翻译： GALECTIN-3和CARDIAC RESYNCHRONIZATION治疗
公开(公告)号：WO2011031493A2
公开(公告)日：2011-03-17
申请号：PCT/US2010/046689
申请日：2010-08-25
申请人： BG MEDICINE, INC. , MUNTENDAM, Pieter
发明人： MUNTENDAM, Pieter
IPC分类号： G01N33/68 , G01N33/15 , G01N33/53
CPC分类号： G01N33/6893 , G01N2333/4724 , G01N2800/325 , G01N2800/52
摘要： The present invention relates to materials and methods for monitoring and predicting a heart failure patient's physiological response to cardiac resynchronization therapy. More specifically, the present invention relates to the endogenous protein galectin-3 and its use in monitoring progression of disease in a patient undergoing cardiac resynchronization therapy, and as a predictor of response to cardiac resynchronization therapy.
摘要翻译：本发明涉及用于监测和预测心脏衰竭患者对心脏再同步治疗的生理反应的材料和方法。更具体地说，本发明涉及内源性蛋白质半乳糖凝集素-3及其在监测进行心脏再同步化治疗的患者中的疾病进展以及作为对心脏再同步化治疗的响应的预测因子的用途。

7. 发明申请

WO2012162531A1 INHIBITORS OF GALECTIN-3 AND METHODS OF USE THEREOF 审中-公开
标题翻译： GALECTIN-3的抑制剂及其使用方法
公开(公告)号：WO2012162531A1
公开(公告)日：2012-11-29
申请号：PCT/US2012/039394
申请日：2012-05-24
申请人： BG MEDICINE, INC. , MUNTENDAM, Pieter
发明人： MUNTENDAM, Pieter
IPC分类号： A61K31/70 , A61K31/7004 , A61K31/7016 , A61K31/702 , A61K31/732 , A61P9/04 , A61K31/00 , A23L1/0524 , A23L1/305 , G01N33/68
CPC分类号： A61K31/70 , A23L29/231 , A23L33/10 , A23V2002/00 , A61K31/00 , A61K31/7004 , A61K31/7016 , A61K31/702 , A61K31/732 , G01N33/6893 , G01N2333/4724 , G01N2500/02 , G01N2800/325 , G01N2800/52 , A23V2200/326 , A23V2250/5072
摘要： Described herein are methods and compositions for inhibiting galectin-3 in a subject. Also described are methods and compositions for treating heart failure.
摘要翻译：本文描述了用于抑制受试者中半乳凝素-3的方法和组合物。还描述了用于治疗心力衰竭的方法和组合物。

8. 发明申请

WO2013120114A1 RISK FACTORS AND PREDICTION OF ADVERSE EVENTS 审中-公开
标题翻译：风险因素和不良事件的预测
公开(公告)号：WO2013120114A1
公开(公告)日：2013-08-15
申请号：PCT/US2013/025763
申请日：2013-02-12
申请人： BG MEDICINE, INC. , ADOURIAN, Aram, S. , GUO, Yu , LI, Xiaohong , MUNTENDAM, Pieter
发明人： ADOURIAN, Aram, S. , GUO, Yu , LI, Xiaohong , MUNTENDAM, Pieter
IPC分类号： G01N33/68
CPC分类号： G06F19/345 , G01N33/6893 , G01N2333/4713 , G01N2333/4737 , G01N2333/705 , G01N2333/775 , G01N2333/79 , G01N2800/2871 , G01N2800/324 , G01N2800/325 , G01N2800/50 , G16H50/20
摘要： Biomarkers, methods, systems, and related teachings are disclosed for diagnosing the risk of an adverse event in a human, where the adverse event can be unstable angina, ischemic stroke, non-ischemic stroke, all-cause stroke, heart failure, all-cause death, and being a candidate for coronary revascularization surgery.
摘要翻译：公开了生物标志物，方法，系统和相关教导，用于诊断人类不良事件的风险，其中不良事件可以是不稳定型心绞痛，缺血性中风，非缺血性中风，全因性中风，心力衰竭，导致死亡，并成为冠状动脉血运重建手术的候选人。

9. 发明申请

WO2010096126A1 GALECTIN-3 IMMUNOASSAY 审中-公开
公开(公告)号：WO2010096126A1
公开(公告)日：2010-08-26
申请号：PCT/US2009/062616
申请日：2009-10-29
申请人： BG MEDICINE, INC. , MUNTENDAM, Pieter
发明人： MUNTENDAM, Pieter
IPC分类号： G01N33/68
CPC分类号： G01N33/6893 , G01N2333/4724 , G01N2800/325
摘要： The present invention relates to methods and compositions for specifically and quantitatively detecting galectin-3 in a sample. Embodiments of the invention include a detection assay in which a capture binding moiety and a labeled binding moiety specifically recognize non-overlapping epitopes on the N-terminus of galectin-3. Further embodiments are directed to a method for establishing ranges of galectin-3 concentrations indicative of the presence and severity of heart failure in a subject and a method for predicting the clinical outcome of a subject based upon galectin-3 concentration.
摘要翻译：本发明涉及用于特异性和定量检测样品中半乳凝素-3的方法和组合物。本发明的实施方案包括其中捕获结合部分和标记的结合部分特异性识别半乳凝素-3的N末端上的非重叠表位的检测测定。另外的实施方案涉及用于建立指示受试者的心力衰竭的存在和严重性的半乳凝素-3浓度的范围的方法以及基于半乳凝素-3浓度来预测受试者的临床结果的方法。

10. 发明申请

WO2009049189A2 METHODS FOR DETECTING MAJOR ADVERSE CARDIOVASCULAR AND CEREBROVASCULAR EVENTS 审中-公开
标题翻译：检测主要不良心血管事件和脑血管事件的方法
公开(公告)号：WO2009049189A2
公开(公告)日：2009-04-16
申请号：PCT/US2008/079553
申请日：2008-10-10
申请人： BG MEDICINE, INC. , MUNTENDAM, Pieter , BALASUBRAMANIAN, Rajalakshmi , MYERS, Rene
发明人： MUNTENDAM, Pieter , BALASUBRAMANIAN, Rajalakshmi , MYERS, Rene
IPC分类号： G01N33/68
CPC分类号： G01N33/6893 , G01N2333/7454 , G01N2800/2871 , G01N2800/32 , G01N2800/325 , G01N2800/60 , H01J49/0009
摘要： The present teachings relate to a method of assessing the probability of a major adverse cardiovascular or cerebrovascular event in a human. The method can include measuring a concentration, in a blood-based sample of a human, of a set of analytes, for example, alpha-fetoprotein, cancer antigen 125, glutathione S-transferase, and tissue factor. The method also can include determining a MACCE index for the set of analytes and identifying the human as having an increased likelihood of a major adverse cardiovascular or cerebrovascular event if the MACCE index is greater than zero, or a decreased likelihood of a major adverse cardiovascular or cerebrovascular event if the MACCE index is less than or equal to zero.
摘要翻译：本教导涉及评估人类主要不利心血管或脑血管事件概率的方法。该方法可以包括测量一组分析物例如甲胎蛋白，癌抗原125，谷胱甘肽S-转移酶和组织因子中人血液样品中的浓度。该方法还可以包括确定该组分析物的MACCE指数，并且如果MACCE指数大于零，则将人识别为具有增加的主要不利心血管或脑血管事件的可能性，或主要不利心血管或如果MACCE指数小于或等于零，脑血管事件。

你已经成功收藏专利！

检索式保存成功!

IPRDB

热门服务

关于我们

友情链接

联系方式